The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Acadia Pharma’s Catherine Owen Adams has formed a group of small- to mid-cap biotechs to advocate against a ‘peanut butter ...

Catalyst Pharmaceuticals recently announced that it was ranked 11th on Forbes’ 2026 list of America’s Most Successful ...

On January 8, 2026, TheFly reported that Morgan Stanley reduced its price target on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) ...

CorMedix CRMD and Puma Biotechnology PBYI are small-cap biotech companies focused on the successful commercialization of their core products as they work to establish leadership within their ...

Join Bristol Myers Squibb, Genentech, Google, J.P. Morgan, Novo Nordisk, Pappas Capital, Amazon Web Services, BIO, Members of ...

aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat ...

Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead candidate.

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies ...

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ...